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Background & Objective: The spread of carbapenem-resistant Pseudomonas 
aeruginosa is a global concern. Metallo-beta-lactamase (MBL) enzymes cause 
extensive drug resistance among Gram-negative bacteria. The current study aimed at 
determining the prevalence of MBL-producing P. aeruginosa in Iran.  
Data extraction: A total of 43 studies were found out of which 36 were adopted. 
Data were collected from Google, Google Scholar, Science Direct, PubMed, Scopus, 
Embase, and Sciverse. The terms “Pseudomonas aeruginosa”, “metallo-beta-
lactamase”, “prevalence”, “carbapenems”, and “Iran” were searched. Data from the 
isolates not producing MBLs were excluded from the study. Data were analyzed with 
Graph Pad Prism 6, meta-analysis section.  
Results: According to the results of the current study, 36 surveys indicated that 
55% of the clinically isolated P. aeruginosa in Iran were resistant to imipenem and 
meropenem, among which 37.72% were the MBL producers. Among genes encoding 
MBLs, blaVIM and blaIMP were predominant with the prevalence of 12.91%±11.01% 
and 12.50%±23.56%, respectively. No report of harboring blaNDM1 and blaSPM1 by P. 
aeruginosa was found, similar to most of the other countries in Asia. The prevalence 
of blaVIM and blaIMP from burn settings were 11.50%±3.5% and 24.65%±23%, 
respectively. Furthermore, the prevalence of these genes was not significantly 
different among burn and non-burn isolates (P=0.942 and P=0.597, respectively). 
Moreover, no relationship was observed between the MBL production and patients’ 
age range.  
Conclusion: Approximately half of P. aeruginosa isolates were carbapenem-
resistant in Iran, and approximately half were the MBL producers. The blaVIM and 
blaIMP were the predominant MBLs among P. aeruginosa strains, while other genes 
were not found in P. aeruginosa. Moreover, there was no significant difference 
between blaVIM and blaIMP among burn and non-burn isolates. Due to the multiple 
drug resistance conferred by MBLs, detection and control of their spread alongside 
proper therapeutic regimens in hospitals and community settings are essential to 
prevent infection acquisition.   
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Introduction 
Carbapenem resistance among clinically isolated 
Pseudomonas aeruginosa (P. aeruginosa) is a great 
concern worldwide, as this class of antibiotics is 
among the last resorts to eradicate infections with  
 
Gram-negative species (1-3). The prevalence of 
multidrug-resistant P. aeruginosa (MDRP) non-
susceptible to quinolones and aminoglycosides in 
addition to beta-lactams is reported worldwide (4-
6). Pseudomonas aeruginosa isolates acquire 
resistance to carbapenems via several mechanisms 
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including overexpression of efflux systems, change 
or lack of outer membrane proteins (such as OprD 
porin), chromosomal AmpC beta-lactamase, and 
production of carbapenemases, overall named 
heteroresistance (7). The most important 
carbapenemases produced by P. aeruginosa are 
zinc-dependent metallo-beta-lactamases (MBLs) 
capable of hydrolyzing imipenem, meropenem, 
ertapenem, and cephalosporins, but not 
monobactams and aztreonam (8, 9). Other types of 
carbapenemases include class D enzymes such as 
OXA-23, OXA-27, OXA-48, and class A including 
clavulanic acid inhibitory enzymes (SME, NMC, 
IMI, and KPC) (10). MBLs are determined in 
Enterobacteriaceae and other Gram-negative non-
fermenters (8). Phenotypic detection of MBLs 
include (1 Combined disk using imipenem and 
imipenem + EDTA (ethylenediaminetetraacetic 
acid)/dipicolinic acid; 2) The Hodge test in which 
Escherichia coli ATCC is lawn on Mueller-Hinton 
agar, and then, test strains are cultured horizontally, 
and 3) The carbaNP test as the most sensitive 
protocol. Carbapenem and vancomycin exposure 
were shown as risk factors for carbapenem-resistant 
P. aeruginosa in Brazil (11). There are various 
MBL genes among carbapenem-resistant P. 
aeruginosa including Verona integron-encoded 
MBL (VIM), Germany imipenemase (GIM), 
imipenemase (IMP), Sao Paulo MBL (SPM), New 
Delhi MBL (NDM), and Florence imipenemase 
(FIM). Each MBL gene is encoded by specific 
genetic elements including transposons, integrons, 
plasmids, or on the chromosome, carrying genes 
encoding determinants of resistance to several 
antibiotics in addition to carbapenems, causing the 
advent of MDR P. aeruginosa. Moreover, these 
genetic determinants are transferable to other Gram-
negative species, extending the antimicrobial 
resistance rate and complicating the treatment of 
infected patients (12). Therefore, it is necessary to 
understand the epidemiology, molecular 
characteristics, and resistance mechanism of MPPA 
to control infection and prevent a possible global 
health crisis. These beta-lactamases are inhibited by 
the EDTA chelator. The most important MBL types 
for epidemiological spread and clinical relevance 
are IMP, VIM, SPM, and currently NDM (13, 14). 
The predominant MBLs are VIM and IMP 
reportedly carried by the mobilizable elements such 
as integrons. The VIM-2 integrons are detected in 
MDR strains (15). It is reported that VIM-type 
MBLs are predominant in some areas (16, 17). The 
blaNDM1 was reported from Klebsiella pneumonia in 
Iran in 2013 (18).  
 
Objectives  
The current study aimed at investigating the 
MBL production and MBL types among clinically 
isolated P. aeruginosa strains in Iran.  
 
Data extraction  
The current meta-analysis review collected data 
from search engines such as Google, Google 
Scholar, Science Direct, PubMed, Scopus, Sciverse, 
etc. The terms “Pseudomonas aeruginosa”, 
“metallo-beta-lactamas “prevalence”, “carbapenems” 
and “Iran” were searched. A total of 43 studies were 
found out of which 36 were adopted. Studies on 
phenotypic results of carbapenem resistance were 
included. All studies on burn isolates were also 
included. Studies on other mechanisms of 
carbapenem resistance were excluded. Data from 
non-metallo-beta-lactamase-mediated carbapenem-
resistant strains were also excluded from the study. 
The prevalence of phenotypic and molecular studies 
was transferred into the software and the results 
were analyzed. The bias among published studies 
were the risk factors, sample size, the outcome of 
infections, the genetic relationship between strains 
in hospital settings (if the infection is clonally 
spread), age, and the economic stats of patients. The 
current study inclusion criteria were the possible 
influence of these risk factors on the prevalence of 
MBL-producing P. aeruginosa alongside the 
genetic characteristics of the strains.  
Data were analyzed using GraphPad Prism 6, 
meta-analysis section, and the standardized mean 
difference by the Cohen d method basically reached 
by the employment of difference score divided by 
standard deviation (SD) of the scores analyzed by 
the software itself.  
 
Results  
The previous studies demonstrated that 55% of 
P. aeruginosa isolates were resistant to 
carbapenems. Of them, 37.72% were MBL-
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positive. The mean prevalence of blaVIM was 
predominant, while only 1% of the strains were 
blaIMP producers and none were positive for blaNDM1 
and blaSPM1 (Table1) (19-26).  
Furthermore, no significant difference was 
observed among burn and non-burn isolates 
regarding the prevalence of MBL genes. There was 
no significant relationship between patients’ age 
ranges and the presence of MBLs. Furthermore, the 
mortality rate due to infection with MBL-producing 
bacteria was not fully elucidated, according to the 
data from some studies (47.25±3795, N=2).   
As already mentioned, the bias among the 
published studies were seldom the detection of risk 
factors, sample size differences, lack of data on the 
outcome of infections, the obscure genetic 
relationship of strains within hospital settings (if the 
infection is clonally spread), weak uncovering ages, 
and the economic status of the patients. Hence, the 
possible risk factors for the acquisition of MBL-
producing P. aeruginosa strains were not 
potentially achieved.  
 
 
 
Table1. Phenotypic and Genotypic Prevalence of MBL Types in Different Cities of Iran  
MBL 
Type 
Percentage 
(%) 
City 
Total 
Isolates 
MR (%) Resistance Year Reference 
VIM 
6.34 
19.51 
17.30 
12.36 
2.62 
13a 
16.1 
2.1a 
32.85 
5.17 
7.5a 
21.3, 24a 
0.46 
Tehran 
Ahvaz 
Tabriz 
Tehran 
Tehran 
Tehran 
Tehran 
Tehran 
Zanjan 
Urmia 
Shiraz 
Arak 
Kermanshah 
126 
100B 
104 
186B 
610 
100B 
483 
483 
70 
58 
240B 
108 
225 
- 
- 
- 
82.6 
- 
 
- 
- 
- 
- 
- 
- 
 
- 
- 
Imipenem 
Imipenem 
Imipenem 
Imipenem 
Imipenem 
Imipenem 
Imipenem 
imipenem 
Imipenem 
Imipenem 
Imipenem 
Imipenem 
Imipenem, 
meropenem 
2007 
2008 
2010 
2010 
2010 
2010 
2012 
2012 
2013 
2013 
2012 
 
2014 
2015 
(27) 
(19) 
(24) 
(22) 
(28) 
(21) 
(29) 
(29) 
(30) 
(31) 
(32) 
(33) 
(34) 
IMP 
5.76 
57.9 
6.6 
3.3b 
14.28 
3.41 
7.5b 
1.3 
15.11 
Tabriz 
Tehran 
Tehran 
Tehran 
Zanjan 
Urmia 
Shiraz 
Tehran 
Kermanshah 
104 
100 
483 
483 
70 
58 
240 
75 
225B 
- 
8.3 
- 
- 
- 
 
- 
- 
- 
- 
Imipenem 
Imipenem 
Imipenem 
Imipenem 
Imipenem 
Imipenem 
Imipenem 
Imipenem 
Imipenem, 
meropenem 
2010 
2013 
2012 
2012 
2013 
 
2013 
2012 
2012 
2015 
 
(26) 
 
 
(30) 
 
 
 
(35) 
(34) 
MBL, metallo-beta-lactamase; aVIM-2; bIMP-2; B isolates from burn injuries; MR, mortality rate   
 
Worldwide incidence of MBL-producing P. 
aeruginosa  
Middle-East and North African countries 
A study by Bahar from Turkey showed the 
presence of VIM-5 beta-lactamase for the first time 
in Klebsiella pneumonia (36). Iraz reported blaGES-
5 and a novel blaVIM variant, named VIM-38 (37).  
Other studies from Saudi Arabia demonstrated the 
presence of VIM-2 in a patients with HIV (38), and 
41% (16/39) blaVIM among the extended-spectrum 
beta-lactamases (ESBL)-producing P. aeruginosa 
(39). Another study revealed that 20.57% (72/350) 
of the isolates produced MBL and all of them  
 
 
carried blaVIM-2 (40). In Egypt, the first report of 
blaNDM-1 associated with blaVIM-2 was published in 
2014 (41). Another study from Egypt revealed that 
39.34% of P. aeruginosa species isolated from 
patients with cancer were imipenem-resistant 
among which 27% were the MBL-positive strains. 
The blaVIM-2, blaNDM-1, and blaIMP-1 were detected 
among 58.3%, 4.2%, and 2.1% of MBL-positive 
isolates (42). The VIM-2 was reported from Tunisia 
and Algeria in North Africa (43-45). In a study in 
Tunisia, of 30 MBL-positive isolates, 17.5% were 
blaVIM-2 positive (46).  
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Asia Pacific 
In a study by Dong in China, among 
59 carbapenem-resistant P. aeruginosa strains, 39 
(66.1%) were positive for the MBL genotype; 35 
(89.7%) and 4 (10.3%) of which carried blaIMP-1 and 
blaVIM-2, respectively (47). Qu showed that among 
24 MBL-producing strains, 10 were positive for 
the blaVIM-2, while 13 were positive for blaIMP-9, and 
1 for blaIMP-1 (48). Yu showed that 14/140 of P. 
aeruginosa species were positive for blaVIM-2; in 
addition 12 of which carried class 1 integrons (49). 
The blaIM-9 was first reported from China in 7 P. 
aeruginosa isolates in 2005 (50). In Southern China, 
only 1 of 61 imipenem-resistant isolates harbored 
blaIMP-9 (51). Of 368 isolates from several cities in 
China, 25 were positive for the blaIMP-6 and 3 
positive for blaVIM-2 with the predominance of 
ST244 and ST235 sequence types (52). The blaKPC-
2 was detected among 38 carbapenemase-producing 
P. aeruginosa isolates exhibiting ST463 (53). In 
Thailand, MBL was clearly positive in 24 (18.46%) 
and weakly positive in 12 (9.23%) isolates; IMP-
1, IMP-14, and VIM-2 were detected among both of 
these sets of isolates (54). In Japan, 11 of 23 
carbapenem-resistant isolates carried GES-5 (55). 
Another study showed that the prevalence of 
blaIMP/(AAC-6)-producing P. aeruginosa increased 
in Japan from 170/300 (56.7%) in 2011 to 230/300 
(76.7%) in 2012 (56). In Korea, 20 (15.6%) and 11 
(8.6%) imipenem non-susceptible isolates were 
positive for blaIMP-1 and blaVIM-2, respectively (57).  
 
European countries  
The blaGIM-1 was first reported from Germany 
among 28% of the isolates in 2004 (58). In the study 
by Valenza in Germany, among 489 isolates, 11.7% 
of MBL-producing isolates were blaVIM-positive, 
but no other encoding gene was detected (59). 
Another study showed the outbreak of blaVIM-2 
among 11 specimens from urinary tract infection in 
Germany (60). There was a case report of NDM-1-
producing P. aeruginosa in France (61). There was 
another report of blaNDM-1 in Balkan region, Serbia 
(62) as well as a report of IMP-29 in France (63). A 
novel MBL named VIM-14 carried in a class 1 
integron with a new organization was detected in 
Italy. The integron harbored the genes aac7, blaVIM-
14, blaOXA-20, and aac4 (64). A novel blaIMP, blaIMP-58, 
was recently reported from Denmark (65).  
 
North America  
The first report of MBL-producing blaVIM-2 in the 
United States was in 2005 (66). The blaNDM was 
reported in some Enterobactericeae isolates in USA 
(67).  
 
Latin America and Africa  
In a study in Brazil, MBLs included SPM-1 
(55.6%), VIM-2 (30.6%), and IMP-1 (8.3%) 
enzymes (68). The NDM-1 was detected in K. 
pneumonia in South Africa (69).  
 
Discussion  
In the current review, the range of MBLs was 
from 16.68% in the study by Shahcheragi to 100% 
in the studies by Bahar and Saderi (21-23). The 
variation between phenotypic and genotypic 
detection of MBLs were not highlighted among 
previous studies from Iran, although it was reported 
by other studies (70). The studies showed that the 
presence of other resistance mechanisms may 
interfere in the MBL phenotypic detection, or 
EDTA can affect cell membrane (71). The NDM1, 
SPM1, and GIM genes are not present in Iran, and 
are reportedly detected in distinct geographic areas 
(5, 72, 73). Rojo Bezares demonstrated that 49.4% 
of carbapenem-resistant P. aeruginosa from Spain 
were MBL-positive, all were blaVIM2-positive, and 
75% were integrin-class1-positive (74). In the study 
by NagKumar, 18.85% of P. aeruginosa isolates 
were MBL-positive. In Colombia, 60% of 
carbapenem-resistant strains were VIM-positive, 
but all were IMP- and NDM-negative, and also class 
1 and 2 were detected among them(75). The GIM1, 
SPM1, and, FIM1 were reported from Germany, 
Switzerland, Brazil, and Italy, respectively (58, 76-
78). The blaVIM is the main MBL encoding gene 
among Middle-East and most of other Asian 
countries. The blaNDM-1 emerged in some countries 
other than India, and thus, its spread is of great 
concern.  
The current study determined no significant 
difference regarding the prevalence of blaIMP and 
blaVIM between the species isolated from burn and 
non-burn injuries.  
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Furthermore, it was not revealed if there was a 
relationship between the prevalence of MBLs and 
patients’ age ranges. In addition, the mortality rate 
was not fully elucidated; however, results of 2 
studies showed a mean rate of 47.25% It was 
depicted that previous antibiotic use, 
catheterization, intravenous (IV) lines, >8 days 
hospital stay, mechanical ventilation, and 
endotracheal intubation were the risk factors for 
MBL-producing P. aeruginosa , but significant risk 
factors for MBL-positives species were graft 
application and surgical intervention (79). As 
already mentioned, the bias among published 
studies seldom detected risk factors, sample size 
differences, lack of the outcome of infections, the 
obscure genetic relationship of strains within 
hospital settings (if the infection was clonally 
spread), and weak uncovering ages and the 
economic status of the patients. For these reasons, 
the possible risk factors for the acquisition of MBL-
producing P. aeruginosa infections were not 
potentially achieved.  
 
Conclusion  
Approximately half of P. aeruginosa isolates 
were carbapenem-resistant in Iran, among which 
nearly half were MBL-positive. The blaVIM and 
blaIMP were the predominant MBLs in P. aeruginosa 
strains, and the emergence of other genes is a 
concern. Moreover, there was no significant 
difference between blaVIM and blaIMP prevalence 
among burn and non-burn injuries. Due to multiple 
drug resistance conferred by MBLs, detection and 
control of their spread alongside proper therapeutic 
regimens in hospital and community settings is 
essential.  
 
Acknowledgments  
This study was supported by Shahrekord 
University of Medical Sciences, Shahrekord, Iran.  
 
 
Conflict of interest  
The authors declared no conflict of interest.  
 
 
 
 
References  
1. Lee Y, Kim C-K, Chung H-S, Yong D, 
Jeong SH, Lee K, et al. Increasing carbapenem-
resistant gram-negative bacilli and decreasing 
metallo-β-lactamase producers over eight years 
from Korea. Yonsei medical journal. 
2015;56(2):572-7. 
2. Davodian E, Sadeghifard N, Ghasemian 
A, Noorbakhsh S. Presence of bla PER-1 and bla 
VEB-1 beta-lactamase genes among isolates of 
Pseudomonas aeruginosa from South West of Iran. 
Journal of epidemiology and global health. 
2016;6(3):211-3. 
3. Davodian E, Sadeghifard N, Ghasemian 
A, Noorbakhsh S. Molecular detection of bla VEB-
1 beta-lactamase encoding gene among extended 
spectrum B-Lactamase positive wound isolates of 
Pseudomonas aeruginosa. Archives of Pediatric 
Infectious Diseases. 2015;3(4). 
4. Yagi H, Tsubaki K. Successful 
treatment with intravenous colistin of sepsis caused 
by metallo-beta-lactamase-producing multidrug-
resistant Pseudomonas aeruginosa in a patient with 
acute myeloid leukemia. Acta Med Kinki Univ. 
2014;39(1):69-73. 
5. Kazmierczak KM, Rabine S, Hackel M, 
McLaughlin RE, Biedenbach DJ, Bouchillon SK, et 
al. Multi-year, multi-national survey of the 
incidence and global distribution of metallo-β-
lactamase-producing Enterobacteriaceae and P. 
aeruginosa. Antimicrobial agents and 
chemotherapy. 2015:AAC. 02379-15. 
6. Saderi H, Owlia P. Detection of 
multidrug resistant (MDR) and extremely drug 
resistant (XDR) P. aeruginosa isolated from patients 
in Tehran, Iran. Iranian journal of pathology. 
2015;10(4):265. 
7. Lister PD, Wolter DJ, Hanson ND. 
Antibacterial-resistant Pseudomonas aeruginosa: 
clinical impact and complex regulation of 
chromosomally encoded resistance mechanisms. 
Clinical microbiology reviews. 2009;22(4):582-
610. 
8. Cornaglia G, Giamarellou H, Rossolini 
GM. Metallo-β-lactamases: a last frontier for β-
lactams? The Lancet infectious diseases. 
2011;11(5):381-93. 
9. Poole K. Pseudomonas aeruginosa: 
resistance to the max. Front Microbiol. 2011;2(65). 
10. Gladstone P, Rajendran P, 
Brahmadathan K. Incidence of carbapenem resistant 
6 Prevalence of Clinically Isolated … 
Vol.13 No.1 Winter 2018                                                                                    IRANIAN JOURNAL OF PATHOLOGY  
nonfermenting gram negative bacilli from patients 
with respiratory infections in the intensive care 
units. Indian journal of medical microbiology. 
2005;23(3):189. 
11. Moniri R, Mosayebi Z, Movahedian 
AH, Mousavi GA. Emergence of multi-drug-
resistant Pseudomonas aeruginosa isolates in 
neonatal septicemia. Journal of Infectious Diseases 
and Antimicrobial Agents. 2005;22(2):39-44. 
12. Hong DJ, Bae IK, Jang I-H, Jeong SH, 
Kang H-K, Lee K. Epidemiology and characteristics 
of metallo-β-lactamase-producing Pseudomonas 
aeruginosa. Infection & chemotherapy. 
2015;47(2):81-97. 
13. Partridge SR, Tsafnat G, Coiera E, 
Iredell JR. Gene cassettes and cassette arrays in 
mobile resistance integrons. FEMS microbiology 
reviews. 2009;33(4):757-84. 
14. Walsh TR, Toleman MA, Poirel L, 
Nordmann P. Metallo-β-lactamases: the quiet 
before the storm? Clinical microbiology reviews. 
2005;18(2):306-25. 
15. Gutiérrez O, Juan C, Cercenado E, 
Navarro F, Bouza E, Coll P, et al. Molecular 
epidemiology and mechanisms of carbapenem 
resistance in Pseudomonas aeruginosa isolates from 
Spanish hospitals. Antimicrobial agents and 
chemotherapy. 2007;51(12):4329-35. 
16. Wright LL, Turton JF, Hopkins KL, 
Livermore DM, Woodford N. Genetic environment 
of metallo-β-lactamase genes in Pseudomonas 
aeruginosa isolates from the UK. Journal of 
Antimicrobial Chemotherapy. 2015:dkv263. 
17. Malkoçoğlu G, Aktaş E, Bayraktar B, 
Otlu B, Bulut ME. VIM-1, VIM-2, and GES-5 
Carbapenemases Among Pseudomonas aeruginosa 
Isolates at a Tertiary Hospital in Istanbul, Turkey. 
Microbial Drug Resistance. 2016. 
18. Shahcheraghi F, Nobari S, Rahmati 
Ghezelgeh F, Nasiri S, Owlia P, Nikbin VS, et al. 
First report of New Delhi metallo-beta-lactamase-1-
producing Klebsiella pneumoniae in Iran. Microbial 
Drug Resistance. 2013;19(1):30-6. 
19. Khosravi AD, Mihani F. Detection of 
metallo-β-lactamase–producing Pseudomonas 
aeruginosa strains isolated from burn patients in 
Ahwaz, Iran. Diagnostic microbiology and 
infectious disease. 2008;60(1):125-8. 
 
20. Owlia P, Saderi H, Karimi Z, Rad A, 
Bagher SM, Bahar MA. Phenotypic detection of 
Metallo-beta-Lactamase producing Pseudomonas 
aeruginosa strains isolated from burned patients. 
Iranian Journal of Pathology. 2008;3(1):20-5. 
21. Saderi H, Lotfalipour H, Owlia P, Salimi 
H. Detection of metallo-β-lactamase producing 
Pseudomonas aeruginosa isolated from burn 
patients in Tehran, Iran. Laboratory Medicine. 
2010;41(10):609-12. 
22. Bahar MA, Jamali S, 
Samadikuchaksaraei A. Imipenem-resistant 
Pseudomonas aeruginosa strains carry metallo-β-
lactamase gene bla VIM in a level I Iranian burn 
hospital. Burns. 2010;36(6):826-30. 
23. Shahcheraghi F, Nikbin VS, Feizabadi 
MM. Identification and genetic characterization of 
metallo-beta-lactamase-producing strains of 
Pseudomonas aeruginosa in Tehran, Iran. The new 
microbiologica. 2010;33(3):243. 
24. Yousefi S, Farajnia S, Nahaei MR, Akhi 
MT, Ghotaslou R, Soroush MH, et al. Detection of 
metallo-β-lactamase–encoding genes among 
clinical isolates of Pseudomonas aeruginosa in 
northwest of Iran. Diagnostic microbiology and 
infectious disease. 2010;68(3):322-5. 
25. Peymani A, Nahaei M-R, Farajnia S, 
Hasani A, Mirsalehian A, Sohrabi N, et al. High 
Prevalence of Metallo-b-Lactamase-Producing 
Acinetobacter baumannii in a Teaching Hospital in 
Tabriz, Iran. Jpn J Infect Dis. 2011;64:69-71. 
26. Fallah F, Borhan RS, Hashemi A. Brief 
Communication Detection of bla (IMP) and bla 
(VIM) metallo-β-lactamases genes among 
Pseudomonas aeruginosa strains. Int J Burn 
Trauma. 2013;3(2):122-4. 
27. Yazdi HR, Nejad GB, Peerayeh SN, 
Mostafaei M. Prevalence and detection of metallo-
β-lactamase (MBL)-producingPseudomonas 
aeruginosa strains from clinical isolates in Iran. 
Annals of microbiology. 2007;57(2):293-5. 
28. Shahcheraghi F, Nikbin VS, Feizabadi 
MM. Identification and genetic characterization of 
metallo-beta-lactamase-producing strains of 
Pseudomonas aeruginosa in Tehran, Iran. New 
Microbiologica. 2010;33(3):243-8. 
29. Boroumand MA, Anvari MS, Habibi E. 
Detection of vim-and ipm-type metallo-beta-
lactamases in Pseudomonas aeruginosa clinical 
isolates. Archives of Iranian medicine. 
2012;15(11):670. 
Abdolmajid Ghasemian et al 7 
Vol.13 No.1 Winter 2018                                                                                    IRANIAN JOURNAL OF PATHOLOGY 
30. Doosti M, Ramazani A, Garshasbi M. 
Identification and characterization of metallo-β-
lactamases producing Pseudomonas aeruginosa 
clinical isolates in University Hospital from Zanjan 
Province, Iran. Iranian biomedical journal. 
2013;17(3):129. 
31. Yousefi S, Nahaei MR, Farajnia S, 
Aghazadeh M, Iversen A, Edquist P, et al. A 
multiresistant clone of Pseudomonas aeruginosa 
sequence type 773 spreading in a burn unit in 
Orumieh, Iran. Apmis. 2013;121(2):146-52. 
32. Sarhangi M, Motamedifar M, Sarvari J. 
Dissemination of Pseudomonas aeruginosa 
producing blaIMP1, blaVIM2, blaSIM1, blaSPM1 
in Shiraz, Iran. Jundishapur Journal of 
Microbiology. 2013;6(7). 
33. Sadeghi A, Rahimi B, Shojapour M. 
Molecular detection of metallo--lactamase genes 
blaVIM-1, blaVIM-2, blaIMP-1, blaIMP-2 and 
blaSPM-1 in Pseudomonas aeruginosa isolated 
from hospitalized patients in Markazi province by 
Duplex-PCR. African Journal of Microbiology 
Research. 2012;6(12):2965-9. 
34. Abiri R, Pantea Mohammadi NS, Rezaei 
M. Detection and Genetic Characterization of 
Metallo-β-Lactamase IMP-1 and VIM-2 in 
Pseudomonas aeruginosa Strains From Different 
Hospitals in Kermanshah, Iran. Jundishapur journal 
of microbiology. 2015;8(9). 
35. Hakemi Vala M, Hallajzadeh M, 
Hashemi A, Goudarzi H, Tarhani M, Sattarzadeh 
Tabrizi M, et al. Detection of Ambler class A, B and 
D ß-lactamases among Pseudomonas aeruginosa 
and Acinetobacter baumannii clinical isolates from 
burn patients. Ann Burns Fire Disasters. 
2014;27(1):8-13. 
36. Bahar G, Mazzariol A, Koncan R, Mert 
A, Fontana R, Rossolini GM, et al. Detection of 
VIM-5 metallo-β-lactamase in a Pseudomonas 
aeruginosa clinical isolate from Turkey. Journal of 
Antimicrobial Chemotherapy. 2004;54(1):282-3. 
37. Iraz M, Duzgun AO, Cicek AC, Bonnin 
RA, Ceylan A, Saral A, et al. Characterization of 
novel VIM carbapenemase, VIM-38, and first 
detection of GES-5 carbapenem-hydrolyzing β-
lactamases in Pseudomonas aeruginosa in Turkey. 
Diagnostic microbiology and infectious disease. 
2014;78(3):292-4. 
 
 
38. Guerin F, Henegar C, Spiridon G, 
Launay O, Salmon-Ceron D, Poyart C. Bacterial 
prostatitis due to Pseudomonas aeruginosa 
harbouring the blaVIM-2 metallo-β-lactamase gene 
from Saudi Arabia. Journal of Antimicrobial 
Chemotherapy. 2005;56(3):601-2. 
39. Al-Agamy MH, Shibl AM, Tawfik AF, 
Elkhizzi NA, Livermore DM. Extended-spectrum 
and metallo-beta-lactamases among ceftazidime-
resistant Pseudomonas aeruginosa in Riyadh, Saudi 
Arabia. Journal of Chemotherapy. 2013. 
40. Al-Agamy MH, Shibl AM, Zaki SA, 
Tawfik AF. Antimicrobial resistance pattern and 
prevalence of metallo--lactamases in Pseudomonas 
aeruginosa from Saudi Arabia. African Journal of 
Microbiology Research. 2011;5(30):5528-33. 
41. Zafer MM, Amin M, El Mahallawy H, 
Ashour MSE-D, Al Agamy M. First report of NDM-
1-producing Pseudomonas aeruginosa in Egypt. 
International Journal of Infectious Diseases. 
2014;29:80-1. 
42. Zafer MM, Al-Agamy MH, El-
Mahallawy HA, Amin MA, Ashour MSE-D. 
Antimicrobial resistance pattern and their beta-
lactamase encoding genes among Pseudomonas 
aeruginosa strains isolated from cancer patients. 
BioMed Research International. 2014;2014. 
43. Touati M, Diene SM, Dekhil M, 
Djahoudi A, Racherache A, Rolain J-M. 
Dissemination of class I integron carrying VIM-2 
carbapenemase gene in Pseudomonas aeruginosa 
clinical isolates from intensive care unit of 
university hospital of Annaba, Algeria. 
Antimicrobial agents and chemotherapy. 
2013:AAC. 00032-13. 
44. Hammami S, Gautier V, Ghozzi R, Da 
Costa A, Ben‐Redjeb S, Arlet G. Diversity in VIM‐
2‐encoding class 1 integrons and occasional 
blaSHV2a carriage in isolates of a persistent, 
multidrug‐resistant Pseudomonas aeruginosa clone 
from Tunis. Clinical Microbiology and Infection. 
2010;16(2):189-93. 
45. Jacobson RK, Minenza N, Nicol M, 
Bamford C. VIM-2 metallo-β-lactamase-producing 
Pseudomonas aeruginosa causing an outbreak in 
South Africa. Journal of Antimicrobial 
Chemotherapy. 2012;67(7):1797-8. 
 
 
 
8 Prevalence of Clinically Isolated … 
Vol.13 No.1 Winter 2018                                                                                    IRANIAN JOURNAL OF PATHOLOGY  
46. Ktari S, Mnif B, Znazen A, Rekik M, 
Mezghani S, Mahjoubi-Rhimi F, et al. Diversity of 
β-lactamases in Pseudomonas aeruginosa isolates 
producing metallo-β-lactamase in two Tunisian 
hospitals. Microbial Drug Resistance. 
2011;17(1):25-30. 
47. Dong F, Xu X-W, Song W-Q, Lü P, Yu 
S-j, Yang Y-h, et al. Characterization of multidrug-
resistant and metallo-beta-lactamase-producing 
Pseudomonas aeruginosa isolates from a paediatric 
clinic in China. Chinese medical journal. 
2008;121(17):1611-6. 
48. Qu T-t, Zhang J-l, Wang J, Tao J, Yu Y-
s, Chen Y-g, et al. Evaluation of phenotypic tests for 
detection of Metallo-β-lactamase-producing 
Pseudomonas aeruginosa strains in China. Journal 
of clinical microbiology. 2009;47(4):1136-42. 
49. Yu Y-S, Qu T-T, Zhou J-Y, Wang J, Li 
H-Y, Walsh TR. Integrons containing the VIM-2 
metallo-β-lactamase gene among imipenem-
resistant Pseudomonas aeruginosa strains from 
different Chinese hospitals. Journal of clinical 
microbiology. 2006;44(11):4242-5. 
50. Xiong J, Hynes MF, Ye H, Chen H, 
Yang Y, M'Zali F, et al. blaIMP-9 and its 
association with large plasmids carried by 
Pseudomonas aeruginosa isolates from the People's 
Republic of China. Antimicrobial agents and 
chemotherapy. 2006;50(1):355-8. 
51. Fang Z-l, Zhang L-y, Huang Y-m, Qing 
Y, Cao K-y, Tian G-b, et al. OprD mutations and 
inactivation in imipenem-resistant Pseudomonas 
aeruginosa isolates from China. Infection, Genetics 
and Evolution. 2014;21:124-8. 
52. Chen Y, Sun M, Wang M, Lu Y, Yan Z. 
Dissemination of IMP-6-producing Pseudomonas 
aeruginosa ST244 in multiple cities in China. 
European journal of clinical microbiology & 
infectious diseases. 2014;33(7):1181-7. 
53. Hu Y-y, Gu D-x, Cai J-c, Zhou H-w, 
Zhang R. Emergence of KPC-2-producing 
Pseudomonas aeruginosa sequence type 463 
isolates in Hangzhou, China. Antimicrobial agents 
and chemotherapy. 2015;59(5):2914-7. 
54. Khuntayaporn P, Montakantikul P, 
Santanirand P, Kiratisin P, Chomnawang MT. 
Molecular investigation of carbapenem resistance 
among multidrug‐resistant Pseudomonas 
aeruginosa isolated clinically in Thailand. 
Microbiology and immunology. 2013;57(3):170-8. 
55. Kanayama A, Kawahara R, Yamagishi 
T, Goto K, Kobaru Y, Takano M, et al. Successful 
control of an outbreak of GES-5 extended-spectrum 
β-lactamase-producing Pseudomonas aeruginosa in 
a long-term care facility in Japan. Journal of 
Hospital Infection. 2016;93(1):35-41. 
56. Tojo M, Tada T, Shimojima M, Tanaka 
M, Narahara K, Miyoshi-Akiyama T, et al. 
Dissemination in Japan of multidrug-resistant 
Pseudomonas aeruginosa isolates producing IMP-
type metallo-β-lactamases and AAC (6′)-Iae/AAC 
(6′)-Ib. Journal of Infection and Chemotherapy. 
2014;20(9):586-8. 
57. Ryoo NH, Ha JS, Jeon DS, Kim JR. 
Prevalence of Metallo-β-lactamases in Imipenem-
non-susceptible Pseudomonas aeruginosa and 
Acinetobacter baumannii. Korean Journal of 
Clinical Microbiology. 2010;13(4):169-72. 
58. Castanheira M, Toleman MA, Jones 
RN, Schmidt FJ, Walsh TR. Molecular 
characterization of a β-lactamase gene, blaGIM-1, 
encoding a new subclass of metallo-β-lactamase. 
Antimicrobial agents and chemotherapy. 
2004;48(12):4654-61. 
59. Valenza G, Joseph B, Elias J, Claus H, 
Oesterlein A, Engelhardt K, et al. First survey of 
metallo-β-lactamases in clinical isolates of 
Pseudomonas aeruginosa in a German university 
hospital. Antimicrobial agents and chemotherapy. 
2010;54(8):3493-7. 
60. Elias J, Schoen C, Heinze G, Valenza G, 
Gerharz E, Riedmiller H, et al. Nosocomial 
outbreak of VIM‐2 metallo‐β‐lactamase‐producing 
Pseudomonas aeruginosa associated with retrograde 
urography. Clinical Microbiology and Infection. 
2010;16(9):1494-500. 
61. Flateau C, Janvier F, Delacour H, Males 
S, Ficko C, Andriamanantena D, et al. Recurrent 
pyelonephritis due to NDM-1 metallo-beta-
lactamase producing Pseudomonas aeruginosa in a 
patient returning from Serbia, France, 2012. Euro 
Surveill. 2012;17(45):20311. 
62. Jovcic B, Lepsanovic Z, Suljagic V, 
Rackov G, Begovic J, Topisirovic L, et al. 
Emergence of NDM-1 metallo-β-lactamase in 
Pseudomonas aeruginosa clinical isolates from 
Serbia. Antimicrobial agents and chemotherapy. 
2011;55(8):3929-31. 
 
 
Abdolmajid Ghasemian et al 9 
Vol.13 No.1 Winter 2018                                                                                    IRANIAN JOURNAL OF PATHOLOGY 
63. Jeannot K, Poirel L, Robert-Nicoud M, 
Cholley P, Nordmann P, Plésiat P. IMP-29, a novel 
IMP-type metallo-β-lactamase in Pseudomonas 
aeruginosa. Antimicrobial agents and 
chemotherapy. 2012;56(4):2187-90. 
64. Mazzariol A, Mammina C, Koncan R, 
Di Gaetano V, Di Carlo P, Cipolla D, et al. A novel 
VIM‐type metallo‐beta‐lactamase (VIM‐14) in a 
Pseudomonas aeruginosa clinical isolate from a 
neonatal intensive care unit. Clinical Microbiology 
and Infection. 2011;17(5):722-4. 
65. Holmgaard DB, Hansen F, Hasman H, 
Justesen US, Hammerum AM. Characterisation of a 
novel bla IMP gene, bla IMP-58, using whole 
genome sequencing in a Pseudomonas 
putida isolate detected in Denmark. 
Diagnostic microbiology and infectious disease. 
2016. 
66. Lolans K, Queenan A, Bush K, Sahud A, 
Quinn J. First nosocomial outbreak of Pseudomonas 
aeruginosa producing an integron-borne metallo-β-
lactamase (VIM-2) in the United States. 
Antimicrobial agents and chemotherapy. 
2005;49(8):3538-40. 
67. Rasheed JK, Kitchel B, Zhu W, 
Anderson KF, Clark NC, Ferraro MJ, et al. New 
Delhi metallo-β-lactamase-producing 
enterobacteriaceae, United States. Emerg Infect Dis. 
2013;19(6):870-8. 
68. Sader HS, Reis A, Silbert S, Gales AC. 
IMPs, VIMs and SPMs: the diversity of metallo‐β‐
lactamases produced by carbapenem‐resistant 
Pseudomonas aeruginosa in a Brazilian hospital. 
Clinical Microbiology and Infection. 
2005;11(1):73-6. 
69. Brink AJ, Coetzee J, Clay CG, Sithole S, 
Richards GA, Poirel L, et al. Emergence of New 
Delhi metallo-beta-lactamase (NDM-1) and 
Klebsiella pneumoniae carbapenemase (KPC-2) in 
South Africa. Journal of clinical microbiology. 
2012;50(2):525-7. 
70. Hawkey PM, Jones AM. The changing 
epidemiology of resistance. Journal of 
Antimicrobial Chemotherapy. 2009;64(suppl 1):i3-
i10. 
71. Geebelen W, Vangronsveld J, Adriano 
DC, Van Poucke LC, Clijsters H. Effects of Pb‐
EDTA and EDTA on oxidative stress reactions and 
mineral uptake in Phaseolus vulgaris. Physiologia 
Plantarum. 2002;115(3):377-84. 
72. Nordmann P, Poirel L. The difficult‐to‐
control spread of carbapenemase producers among 
Enterobacteriaceae worldwide. Clinical 
Microbiology and Infection. 2014;20(9):821-30. 
73. Hong JS, Kim JO, Lee H, Bae IK, Jeong 
SH, Lee K. Characteristics of metallo-β-lactamase-
producing Pseudomonas aeruginosa in Korea. 
Infection & chemotherapy. 2015;47(1):33-40. 
74. Rojo-Bezares B, Estepa V, Cebollada R, 
de Toro M, Somalo S, Seral C, et al. Carbapenem-
resistant Pseudomonas aeruginosa strains from a 
Spanish hospital: characterization of metallo-beta-
lactamases, porin OprD and integrons. International 
Journal of Medical Microbiology. 2014;304(3):405-
14. 
75. Martinez E, Pérez JE, Buelvas F, Tovar 
C, Vanegas N, Stokes H. Establishment and multi 
drug resistance evolution of ST235 Pseudomonas 
aeruginosa strains in the intensive care unit of a 
Colombian hospital. Research in microbiology. 
2014;165(10):852-6. 
76. Wendel AF, Brodner AH, Wydra S, 
Ressina S, Henrich B, Pfeffer K, et al. Genetic 
characterization and emergence of the metallo-β-
lactamase GIM-1 in Pseudomonas spp. and 
Enterobacteriaceae during a long-term outbreak. 
Antimicrobial agents and chemotherapy. 
2013;57(10):5162-5. 
77. El Salabi A, Toleman MA, Weeks J, 
Bruderer T, Frei R, Walsh TR. First report of the 
metallo-β-lactamase SPM-1 in Europe. 
Antimicrobial agents and chemotherapy. 
2010;54(1):582-. 
78. Pollini S, Maradei S, Pecile P, Olivo G, 
Luzzaro F, Docquier J-D, et al. FIM-1, a new 
acquired metallo-β-lactamase from a Pseudomonas 
aeruginosa clinical isolate from Italy. Antimicrobial 
agents and chemotherapy. 2013;57(1):410-6. 
79. Kumar SH, De AS, Baveja SM, Gore 
MA. Prevalence and risk factors of metallo β-
lactamase producing Pseudomonas aeruginosa and 
Acinetobacter species in burns and surgical wards 
in a tertiary care hospital. Journal of laboratory 
physicians. 2012;4(1):39. 
 
Ghasemian, A., Salimian Rizi, K., Rajabi Vardanjani, H., Nojoomi, F. Prevalence of Clinically Isolated Metallo-
beta-lactamase-producing Pseudomonas aeruginosa, Coding Genes, and Possible Risk Factors in Iran. Iran J Pathol. 
2018;13(1): 1-9. 
